JP6729917B2 - ＥｐｈＡ２ Ｎ末端フラグメント抗体 - Google Patents

ＥｐｈＡ２ Ｎ末端フラグメント抗体 Download PDF

Info

Publication number
JP6729917B2
JP6729917B2 JP2018534429A JP2018534429A JP6729917B2 JP 6729917 B2 JP6729917 B2 JP 6729917B2 JP 2018534429 A JP2018534429 A JP 2018534429A JP 2018534429 A JP2018534429 A JP 2018534429A JP 6729917 B2 JP6729917 B2 JP 6729917B2
Authority
JP
Japan
Prior art keywords
epha2
amino acid
acid sequence
antibody
mmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018534429A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2018034332A1 (ja
Inventor
直彦 越川
直彦 越川
元治 清木
元治 清木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION
Original Assignee
University of Tokyo NUC
KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC, KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION filed Critical University of Tokyo NUC
Publication of JPWO2018034332A1 publication Critical patent/JPWO2018034332A1/ja
Application granted granted Critical
Publication of JP6729917B2 publication Critical patent/JP6729917B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018534429A 2016-08-19 2017-08-18 ＥｐｈＡ２ Ｎ末端フラグメント抗体 Active JP6729917B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016161191 2016-08-19
JP2016161191 2016-08-19
PCT/JP2017/029596 WO2018034332A1 (fr) 2016-08-19 2017-08-18 ANTICORPS FRAGMENT DE L'EXTRÉMITÉ N-TERMINALE EphA2

Publications (2)

Publication Number Publication Date
JPWO2018034332A1 JPWO2018034332A1 (ja) 2019-06-20
JP6729917B2 true JP6729917B2 (ja) 2020-07-29

Family

ID=61196754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018534429A Active JP6729917B2 (ja) 2016-08-19 2017-08-18 ＥｐｈＡ２ Ｎ末端フラグメント抗体

Country Status (2)

Country Link
JP (1) JP6729917B2 (fr)
WO (1) WO2018034332A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
WO2001012172A1 (fr) * 1999-08-17 2001-02-22 Purdue Research Foundation Traitement de maladies metastatiques
WO2001012840A2 (fr) * 1999-08-17 2001-02-22 Purdue Research Foundation Anticorps utilises dans le diagnostic du cancer
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット

Also Published As

Publication number Publication date
JPWO2018034332A1 (ja) 2019-06-20
WO2018034332A1 (fr) 2018-02-22

Similar Documents

Publication Publication Date Title
US9840551B2 (en) Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
JP2008513536A (ja) プロガストリンに対するモノクローナル抗体
KR101832199B1 (ko) 악성 종양의 진단 방법
US10809263B2 (en) Antigenic composition for detecting auto-antibody with specific response to exosomal protein EIF3A, and method for diagnosing liver cancer using antigenic composition
WO2014144060A1 (fr) Anticorps monoclonaux dirigés contre la transferrine et antigènes du récepteur de la transferrine, et leurs utilisations
JP2012524521A (ja) グリコデリンモノクローナル抗体および卵巣癌の検出におけるその使用のための方法
JP6977105B2 (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
CA3009768A1 (fr) Compositions et procedes d'evaluation du risque d'apparition d'un cancer
JP5002001B2 (ja) インスリンレセプターαサブユニットの測定方法
SG177514A1 (en) New tumor marker
JP6276992B2 (ja) 胸膜中皮腫患者の早期発見のための分子マーカー及びその発現解析方法
KR101777259B1 (ko) En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
EP2738250B1 (fr) Anticorps anti-beta1,6-N-acetylglucosaminyltransferase 5B pour la détection du cancer épithélial de l'ovaire et méthode pour le diagnostic du cancer épithélial de l'ovaire
JP6729917B2 (ja) ＥｐｈＡ２ Ｎ末端フラグメント抗体
CN111303289B (zh) 抗人Tn型糖基化MUC1抗体及其用途
JP6425397B2 (ja) Ｎｌｒｒ１細胞外ドメインタンパク質を検出する方法
JP7565046B2 (ja) がんの骨転移を検出する方法及び検出試薬
CN105474016B (zh) Augurin免疫试验
US9127054B2 (en) Immunoassay of cofilin 1 protein
EP2738252B1 (fr) Anticorps pour la détection d'un marqueur du cancer épithélial de l'ovaire et méthode pour le diagnostic du cancer épithélial de l'ovaire
JP2004198313A (ja) 甲状腺腫瘍の診断用キット
US20130130276A1 (en) Method for detecting gastric cancer
US20120282633A1 (en) Antibody specific to activated egfr
US20100093005A1 (en) Identifying duct cancers
AU2014203702B2 (en) New tumor marker

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200626

R150 Certificate of patent or registration of utility model

Ref document number: 6729917

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250